Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents.

Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents.
复制标题

DOI:
10.1021/ml3003082
复制
发表时间:
2013-02-14
影响因子:
4.2
通讯作者:
Zhou, Jia
Zhou, Jia
中科院分区:
医学3区
文献类型:
--
作者:
Chen, Haijun;Yang, Zhengduo;Ding, Chunyong;Chu, Lili;Zhang, Yusong;Terry, Kristin;Liu, Huiling;Shen, Qiang;Zhou, Jia

文献摘要

参考文献

被引文献

相似文献

氯硝柳胺已被鉴定为有效抑制STAT 3的活化、核转位和反式激活。然而,氯硝柳胺的水溶性和生物利用度差,阻碍了其在癌症治疗中的进一步临床开发。为了发现具有增强的药物样性质的新分子,已经设计、合成了一系列新颖的氯硝柳胺的O-烷氨基栓系衍生物,并进行了生物学评价。其中,化合物11(HJC 0152)已被证明在体内(i. p.& p.o.)显著抑制MDA-MB-231异种移植肿瘤生长,表明其作为人类癌症的有效和口服生物可利用的治疗剂的巨大潜力。
Niclosamide has been identified to potently inhibit the activation, nuclear translocation, and transactivation of STAT3. Nevertheless, the poor aqueous solubility and bioavailability of niclosamide has hindered its further clinical development for cancer therapy. To discover new molecules with enhanced drug-like properties, a series of novel O-alkylamino tethered derivatives of niclosamide have been designed, synthesized, and biologically evaluated. Among them, compound 11 (HJC0152) has been demonstrated to significantly suppress MDA-MB-231 xenograft tumor growth in vivo (i.p. & p.o.), indicating its great potential as efficacious and orally bioavailable therapeutics for human cancer.
DOI: 10.1021/jm0706416
发表时间: 2007-11-15
影响因子: 7.3
作者:
Bergstroem, Christel A. S.;Wassvik, Carola M.;Hubatsch, Ina
通讯作者: Hubatsch, Ina
DOI: 10.1194/jlr.m800539-jlr200
发表时间: 2009-08-01
影响因子: 6.5
作者:
Navab, Mohamad;Ruchala, Piotr;Fogelman, Alan M.
通讯作者: Fogelman, Alan M.
DOI: 10.1021/jm300207s
发表时间: 2012-08-09
影响因子: 7.3
作者:
Debnath, Bikash;Xu, Shili;Neamati, Nouri
通讯作者: Neamati, Nouri
DOI: 10.1172/jci200215617
发表时间: 2002-05-01
影响因子: 15.9
作者:
Bromberg, J
通讯作者: Bromberg, J
DOI: 10.1126/science.277.5332.1630
发表时间: 1997-09-12
期刊: SCIENCE
影响因子: 56.9
作者:
Darnell, JE
通讯作者: Darnell, JE